NeoImmuneTech, Inc. Logo

NeoImmuneTech, Inc.

A clinical-stage biopharma developing T cell-focused immuno-therapeutics for diseases.

950220 | KO

Overview

Corporate Details

ISIN(s):
KR8840140006
LEI:
Country:
United States of America
Address:
2400 Research Boulevard, Suite 250, Rockville, MD 20850, Rockville

Description

NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-08-21 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.2 KB
2025-08-21 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.2 KB
2025-08-20 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.0 KB
2025-08-20 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 99.8 KB
2025-08-20 00:00
[기재정정]증권신고서(증권예탁증권)
Korean HTML 3.1 MB
2025-08-19 00:00
투자판단관련주요경영사항(임상시험결과) (NIT112 (거대 B세포 림프종, NTI7 및 CART 치료제 병용 요법) 임…
Korean HTML 22.7 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean HTML 1.2 MB
2025-07-30 00:00
유상증자1차발행가액결정
Korean HTML 8.8 KB
2025-07-30 00:00
[발행조건확정]증권신고서(증권예탁증권)
Korean HTML 196.8 KB
2025-07-30 00:00
[기재정정]투자설명서
Korean HTML 2.6 MB
2025-07-30 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean HTML 35.6 KB
2025-07-30 00:00
권리락 (유상증자)
Korean HTML 3.5 KB
2025-07-30 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean HTML 34.2 KB
2025-07-21 00:00
기업설명회(IR)개최
Korean HTML 8.8 KB
2025-07-18 00:00
임원ㆍ주요주주특정증권등거래계획보고서
Korean HTML 42.6 KB

Automate Your Workflow. Get a real-time feed of all NeoImmuneTech, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeoImmuneTech, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeoImmuneTech, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.